Assessment of Pulmonary Arterial Hypertension (PAH) Risk in Sickle Cell Disease Patients Using Plasma Apolipoproteins

Science-Business eXchange

doi 10.1038/scibx.2008.1119

Full Text

Abstract

Available in

Date

December 1, 2008

Authors

Unknown

Publisher

Springer Science and Business Media LLC

Related search

Pulmonary Hypertension in Sickle Cell Disease

New England Journal of Medicine

English

P2 In-Flight Hypoxaemia in Patients With Pulmonary Arterial Hypertension (PAH)

Respiratory Medicine

English

Sildenafil Therapy in Patients With Sickle Cell Disease and Pulmonary Hypertension

British Journal of Haematology

English

Risk Assessment in Patients With Systemic Sclerosis and Pulmonary Arterial Hypertension

European Respiratory Journal

Respiratory Medicine

English

Relative Systemic Hypertension in Patients With Sickle Cell Disease Is Associated With Risk of Pulmonary Hypertension and Renal Insufficiency

American Journal of Hematology

English

Preoperative Risk Assessment of Pulmonary Arterial Hypertension Patients Undergoing General Surgery

Advances in Pulmonary Hypertension

English

Clinical Profiling of Sickle Cell Disease Patients With Respect to Pulmonary Hypertension

International Journal of Scientific Reports

English

Endothelin Receptor Antagonists for Pulmonary Hypertension in Adult Patients With Sickle Cell Disease

British Journal of Haematology

English

Effects of Inhaled Aviptadil (Vasoactive Intestinal Peptide) in Patients With Pulmonary Arterial Hypertension (PAH)

English